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0. Summary 
 
Ireland maintains a special register which is a complete census of all drug-induced deaths.  Opiates 
are the main drug associated with drug-induced deaths. 
 
Data on drug-related acute emergencies in the Irish context refer to all admissions to acute general 
hospitals with non-fatal overdoses and are extracted from the Hospital In-Patient Enquiry (HIPE) 
scheme.  
 
Incidences of newly diagnosed HIV, HBV and HCV are notified to the Health Protection Surveillance 
Centre (HPSC).  Notification data for 2014 are included in this report. 
 
The number of drug-induced deaths has fluctuated over the past five years but overall the trend is 
upwards.  The majority of those who died were male, aged in their thirties.  Between 2009 and 2013 
opiates were the most common drug associated with most drug-induced deaths as per the 
EMCDDA Filter D inclusion criteria.  In 2013, the number of deaths where heroin was implicated 
increased for the first time since 2009.  
 
Trends over time indicate a decrease in overdose cases admitted to Irish hospitals, falling from 
5,012 cases in 2005 to 4,233 cases in 2013, a reduction of 779 cases. 
 
Since June 2014 there has been an increase in notifications of recently acquired HIV in people who 
inject drugs (PWID) in Dublin.  This is possibly linked with injection of a synthetic cathinone PVP but 
epidemiological investigation is still under way. In addition, enhanced infection control measures are 
being implemented. 
 
A naloxone demonstration project is currently under way in the country. The aim of the project is to 
assess and evaluate the suitability and impact of using naloxone in Ireland in order to make 
naloxone more widely available for problem opiate users.  
 
Since the pharmacy-based needle exchange programme was established the number of 
participating pharmacies has grown from 42 in 2011 to 99 at the end of 2013.  The number of 
people attending this service has also increased from on average 306 per month in 2012 to 933 per 
month in 2013. 
 
1. National profile 
1.1 Drug-related deaths  
1.1.1 Overdose deaths 
In 2013, there were 219 deaths owing to poisoning recorded in Ireland by the National Drug-Related 
Deaths Index (NDRDI). This represents a 16% increase compared to the 189 deaths reported in 
2012. It should be noted that annual data previously reported have been changed as the NDRDI 
figures have been updated as new information has become available. 
 
Overall, the mean age of those who died (36.5 years) owing to poisoning remained stable compared 
to 2012 (36.3 years).  The mean age of those who died has gradually increased over the past 10 
years from 31.7 years in 2004 to 36.5 in 2013. The majority of deaths were male (74.9%) similar to 
previous years. 
 
The NDRDI does not routinely report the intentionality of the death. 
 
1.1.2 Toxicology of overdose deaths 
In 2013, opiates continue to be associated with most poisoning deaths (186/219, 84.9%) similar to 
previous years. Methadone (alone or with another drug) continues to be the opiate most commonly 
implicated in poisoning deaths. In 2013, there were 93 deaths where methadone was implicated, 
compared to 89 deaths in 2012.  This is compared to a peak in 2011 when there were 119 deaths 
where methadone was implicated.  
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In 2013 there were 86 deaths where heroin was implicated, compared to 64 in 2012.  This 
represents a 34% increase between the two years. This is the first increase in heroin-related deaths 
since 2009. There were 31 deaths where cocaine was implicated (alone or with another drug), a 
small increase on the 26 reported in 2012.  
 
The majority of poisoning deaths (77.2%) in 2013 involved more than one drug. As in previous 
years, benzodiazepines, alcohol, antidepressants and other prescriptions medications were among 
the main drugs implicated in poly-substance poisonings. 
 
Toxicology was available for 187 deaths in 2013. Opiates were found in the post-mortem toxicology 
of 90.3% (169/187) of these deaths. 
1.1.3 Additional information on drug-related deaths 
The National Drug Related Deaths Index (NDRDI) also publishes national figures on drug-related 
deaths. This comprises all deaths owing to poisonings, including both illicit drugs but also other 
drugs such as alcohol and prescription medication. It also includes data on non-poisoning deaths 
among drug users (Health Research Board 2015). 
 
The number of drug related deaths and deaths among drug users has increased slightly from 658 in 
2012 to 679 in 2013. Of the total number of deaths in 2013, 387 people died as a result of poisoning 
(i.e. toxic effect of drug[s] in the body), and 292 were drug users who died as a result of trauma, 
such as hanging, or from a medical cause, for example liver disease. It is important to note that the 
figures in this update supersede all previously published figures. Similarly, figures for 2013 will be 
revised when data relating to new cases become available, i.e. as more inquest cases close.  
 
In the nine-year period 2004–2013, a total of 6,002 deaths by drug poisoning and deaths among 
drug users met the criteria for inclusion in the NDRDI database. Of these deaths, 3,519 were due to 
poisoning and 2,483 were deaths among drug users (non-poisoning). Deaths owing to polydrug use 
have increased by 98% over the reporting period, from 118 in 2004 to 234 in 2013. 
 
Poisoning deaths, 2013 
The annual number of poisoning deaths increased from 361 in 2012 to 387 in 2013.  As in previous 
years, the majority (68%) in 2013 were male; the median age of those who died was 41 years, 
slightly older to previous years.  
 
In 2013, alcohol was, once again, the drug most commonly involved in poisoning deaths (35%) 
nationally. Prescription drugs played a significant part in poisoning deaths, two fifths (41%) of these 
deaths involving benzodiazepines. Methadone was implicated in a quarter of deaths, with the 
majority (94%) involving polydrug use.  
 
There were 86 deaths where heroin was implicated (22% of all poisoning deaths). This is the first 
time since 2009 that the number of heroin-related deaths has increased. Over two fifths (42%) of 
people who died where heroin (injecting or smoking) was implicated were not alone at the time they 
took the drug, therefore there may have been an opportunity to prevent deaths. Half (49%) of those 
who died from a heroin-related death were known to be injecting at the time of their death. 
 
Over half (60%) of all poisoning deaths in 2013 involved more than one drug (polydrug use).  Over 
two fifths (43%) of those who died from poisoning in 2013 had a history of mental illness. 
 
Non-poisoning deaths, 2013 
The number of non-poisoning deaths recorded among drug users decreased slightly in 2013 to 292 
deaths compared to 295 in 2012. Where the specific cause of death is known, these deaths are 
categorised as being due to either trauma or medical causes. 
 
Deaths owing to trauma 
The number of deaths owing to trauma decreased slightly in 2013 to 292 deaths compared to 295 in 
2012. Death due to hanging accounted for 25% (n = 74) of all non-poisoning deaths. More than half 
(44, 59%) of deaths due to hanging in 2013 had a history of mental health illness.  
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Deaths owing to medical causes 
The most common medical cause of death in 2013 was deaths due to cardiac events, accounting 
for almost a fifth (52, 18%) of all non-poisoning deaths. A younger cohort died from traumatic 
causes (median age of 34 years) in comparison to deaths due to medical causes (median age of 47 
years).  
1.2 Drug related acute emergencies 
1.2.1 Drug-related acute emergencies 
Monitoring of drug-related acute emergencies in the Irish context refers to all admissions to acute 
general hospitals in Ireland with non-fatal overdoses.  See Section 6.1 below for a description of the 
main monitoring systems and sources of data.  
1.2.2 Toxicology of drug-related acute emergencies 
 
Drug related emergencies – non-fatal overdoses 
Data extracted from the Hospital In-Patient Enquiry (HIPE) scheme were analysed to determine 
trends in non-fatal overdoses discharged from Irish hospitals in 2013. There were 4,270 overdose 
cases in that year, of which 37 died in hospital.  Only the 4,233 discharged cases are included in 
this analysis.  The number of overdose cases decreased by 4% between 2012 and 2013. Trends 
over time indicate a decrease in overdose cases admitted to Irish hospitals, falling from 5,012 cases 
in 2005 to 4,233 cases in 2013, a reduction of 779 cases (Figure 1.2.2.1). 
 
 
Figure 1.2.2.1 Overdose cases admitted to Irish hospitals, 2005–2013 (N=41,111) 
Source: HIPE unpublished data, 2015 
 
Gender 
Between 2005 and 2013 there were more overdose cases among women than among men, with 
women accounting for 2,311 (55%) of all non-fatal overdose cases in 2013 (Figure 1.2.2.2). 
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Figure 1.2.2.2 Overdose cases admitted to Irish hospitals, by gender, 2005–2013 (N=41,111) 
Source: HIPE unpublished data, 2015 
 
Age group 
There was an increase in the number of non-fatal overdose cases among those aged 24 or under, 
those aged 65 to 74 years and those aged over 85 years between 2012 and 2013. There was a 
decrease in all other age groups. The incidence of overdose peaked in the 15 to 24 age category 
and thereafter decreased with age (Figure1.2.2.3).  Trends over time show that in 2005, 40% of 
cases were aged less than 25 years compared to 34% in 2013. 
 
 
Figure 1.2.2.3 Overdose cases admitted to Irish hospitals, by age group, 2005–2013 (N=41,111) 
2005 2006 2007 2008 2009 2010 2011 2012 2013
Female 2794 2605 2691 2640 2258 2374 2286 2436 2311
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Source: HIPE unpublished data, 2015 
 
Drugs involved 
Table 1.2.2.1 presents the positive findings per category of drugs and other substances involved in 
all cases of overdose in 2013. 
 
Non-opioid analgesics were present in 35% (1,482) of cases. Paracetamol is included in this drug 
category and was present in 28% (1,174) of cases.  Psychotropic agents were taken in 24% (999) 
and benzodiazepines in 19% (818) of cases. There was evidence of alcohol consumption in 9% 
(365) of cases. Cases involving alcohol are included in this analysis only when the alcohol was used 
in conjunction with another substance.  
 
Table 1.2.2.1 Categories of drugs involved in overdose cases admitted to Irish hospitals, 2013 (N= 4,233)* 
Drug category Number % 
Non-opioid analgesics 1,482 35.0 
Benzodiazepines 818 19.3 
Psychotropic agents 999 23.6 
Antiepilepic/Sedative/Antiparkinson agents 1,940 45.8 
Narcotics and hallucinogens 587 13.9 
Alcohol 365 8.6 
Systemic and haematological agents 140 3.3 
Cardiovascular agents 139 3.3 
Autonomic nervous system 119 2.8 
Anaesthetics 8 0.2 
Hormones 134 3.2 
Systemic antibiotics 71 1.7 
Gastrointestinal agents 65 1.5 
Other chemicals and noxious substances 288 6.8 
Diuretics 54 1.3 
Muscle and respiratory agents 40 0.9 
Topical agents 46 1.1 
Anti-infectives / Anti-parasitics 29 0.7 
Other gases and vapours 52 1.2 
Other and unspecified drugs 878 20.7 
Source: HIPE unpublished data, 2015 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one drug or substance. 
 
Overdoses involving narcotics or hallucinogens 
Narcotic or hallucinogenic drugs were involved in 14% (587) of overdose cases in 2013. Figure 
1.2.2.4 shows the number of positive findings of narcotics or hallucinogens drugs among the 587 
cases. Opiates were used in 80% (468) of the cases, cocaine in 10% (60) and cannabis in 10% (60) 
of cases. 
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Figure 1.2.2.4 Narcotics and hallucinogens involved in overdose cases admitted to Irish hospitals, 2013 (N=587)*  
Source: HIPE unpublished data, 2015 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one drug from this 
category.   
 
Overdoses classified by intent 
In 63% (2,682) of cases the overdose was classified as intentional (Figure 1.2.2.5).  For 24 cases, 
classification of intent was not clear. These cases were not included in the analysis. 
 
Figure 1.2.2.5 Overdose cases admitted to Irish hospitals, classified by intent, 2013 (N=4,209) 
Source: HIPE unpublished data, 2015 
 
Table 1.2.2.2 presents the positive findings per category of drugs and other substances involved in 
cases of intentional self-poisoning (n=2,682) in 2013. Non-opioid analgesics were involved in 42% 
(1,122) of cases, benzodiazepines in 23% (615) and psychotropic agents in 28% (748).  
 
Table 1.2.2.2 Categories of drugs involved in intentional self-poisoning cases admitted to Irish hospitals, 2013 (N= 
2,682)* 
Drug category Number % 
Non-opioid analgesics 1,122 41.8 
Benzodiazepines 615 22.9 
Psychotropic agents 748 27.9 
Antiepileptic/Sedative/Antiparkinson agents 1,430 53.3 
Narcotics and hallucinogens 336 12.5 
Alcohol 255 9.5 
Systemic and haematological agents 75 2.8 
Cardiovascular agents 86 3.2 
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Autonomic nervous system 75 2.8 
Anaesthetics 4 0.1 
Hormones 88 3.3 
Systemic antibiotics 46 1.7 
Gastrointestinal agents 49 1.8 
Other chemicals and noxious substances 78 2.9 
Diuretics 26 1.0 
Muscle and respiratory agents 13 0.5 
Topical agents 7 0.3 
Anti-infectives / Anti-parasitics 15 0.6 
Other gases and vapours 6 0.2 
Other and unspecified drugs 507 18.9 
Source: HIPE unpublished data, 2015 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one drug 
or substance. 
 
 
1.2.3 Additional information on drug-related acute emergencies 
 
Urban overdose hotspots in Dublin 
A recent study looked at opioid overdoses in Dublin in order to understand more fully the risk factors 
involved, to help reduce the associated mortality and morbidity and to improve the response to such 
incidents (Klimas J, et al. 2014). The study had two aims: to establish a baseline incidence of all 
new overdoses that Dublin ambulances attend, and to look at the relationship between geographical 
location of overdoses, deprivation and location of methadone clinics.  
 
There are two ambulance services in Dublin: the Dublin Fire Brigade (DFB), and the National 
Ambulance Service (NAS) operated by the Health Service Executive (HSE).  Ambulance staff enter 
data on each individual that they attend on a patient care report (PCR).  The PCR is a paper-based 
record of the pre-hospital care given by ambulance staff/first responders. All PCRs for a 12-month 
period in 2012–2013 were reviewed prospectively to identify opioid overdoses.  All relevant data 
were extracted: clinical presentation; clinical care provided; administration of naloxone; response to 
naloxone; whether the patient was taken to hospital; and death, if confirmed by ambulance staff on 
scene.  Follow-up data on patients who were taken to emergency departments were not collected 
for this study. 
The locations of overdoses were categorised as ‘street’, ‘residential’ (house/hotel) or ‘service’ 
(homeless shelter, treatment centre, hospital, shop, pub, Garda station).  DFB personnel assigned 
geographic co-ordinates for the location of every overdose attended.  These data were not available 
for attendances by the NAS. 
Over the study period, ambulances attended 469 opioid overdoses.  This gives an overdose 
incidence of 4.9 cases per 1,000 cases per year.   
Characteristics of patients who overdosed: 
 80% male 
 Mean age 33 years 
 Evidence of opiate use was observed in 89%. 
 Evidence of use of other drugs, mainly alcohol, was observed in 28%.  
 45% of patients were attended on the street. 
 38% were attended in a residential location. 
 70% were attended during the day. 
 27% were repeat overdoses. 
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Data on clinical presentation of the patient: 
 39% were unresponsive. 
 10% were in respiratory arrest. 
 12% had respiratory depression. 
 4% were in cardiac arrest. 
 Mean GCS score: 2  
o Pre-intervention 7.2 
o Post-intervention 12.3 
 3% were confirmed dead at the scene. 
Type of intervention provided: 
 76% had naloxone administered: 
 66% given naloxone intramuscularly 
 Mean number of doses 1.5 
 22% had assisted ventilation. 
 60% were administered oxygen. 
 89% were transported to hospital. 
Geographic location of overdoses: 
 86% Dublin city centre 
 6% South Dublin 
 5% Fingal 
 1% Dun Laoghaire 
The relationship between overdose and deprivation was examined using the Pobal-Haase-
Pratschke Deprivation Index and pre-existing Small Area (SA) boundaries. The Deprivation Index is 
a composite score ‘measuring the relative affluence or disadvantage of a particular geographic 
area’.  The score ranges from -40 (most disadvantaged) to +40 (most affluent).  Each overdose was 
mapped to its corresponding SA. There were some statistically significant differences found 
between the number of overdoses and level of area affluence, with a greater number of overdoses 
occurring in less affluent areas, and the locations where overdoses occurred, with overdoses 
occurring in residential locations having a lower deprivation score than overdoses occurring in street 
locations. 
The study also looked at the location of methadone clinics in relation to overdoses.  This showed 
that most overdoses occurred within a 1,000-metre radius of certain methadone clinics.   
The authors identified some limitations to the study.  PCR forms were not always reliable (they were 
hand-written under stressful circumstances and often involved difficult decisions) and data could not 
be validated.  Geo-data were not available for NAS PCRs. 
The results of the study highlight several issues which can help inform decisions about preventing 
overdose deaths.  Dublin ambulance services attended an opioid overdose almost daily; the 
majority occurred in Dublin city centre, on the street, during the day and near certain methadone 
clinics; street overdoses were more likely to occur in the city centre and on the quays, while 
residential overdoses were more likely to occur in the suburbs.  Clinical findings showed patients 
had low mean GCS scores pre-intervention, meaning that many patients were unconscious.  
However, the mean GCS scores post-intervention showed improvement, indicating the 
effectiveness of the intervention given by the ambulance staff. However, the results also showed 
that the GCS scores of 25% of patients did not improve after administration of naloxone.   
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Despite international research indicating that overdose prevention and naloxone distribution 
programmes can help to reduce overdose deaths, not many countries provide such programmes.  
The authors stated that the results point to the need for such a programme, based in the 
community, in Ireland.  
Drug admissions to psychiatric facilities 
Activities of Irish psychiatric units and hospitals 2013, the annual report published by the Mental 
Health Information Systems Unit of the Health Research Board in 2014, shows that the total number 
of admissions to inpatient care in 2013 had increased slightly since 2012.  However, there was a 
17% decline in overall psychiatric admissions in the 10 years between 2004 and 2013 (Daly and 
Walsh 2014). 
 
In 2013, 890 cases were admitted to psychiatric facilities with a drug disorder (ICD-10 code F11-19, 
F55), which is a rate of 19.4 per 100,000 total population.   Of these, 365 (41%) were treated for the 
first time. This is similar to the number of admissions in 2012 when there were 831 cases of which 
358 were for the first time.  The report does not present data on drug use and psychiatric co-
morbidity, so it is not possible to determine whether or not these admissions were appropriate.  
Figure 1.2.3.1 presents the rates of first admission between 1994 and 2013 of cases with a 
diagnosis of drug disorder. 
 
Figure 1.2.3.1: Rates of psychiatric first-admission cases with a diagnosis of drug disorder per 100,000 of the 
population in Ireland, 1994–2013 
Source: (Daly and Walsh 2014)  
 
Other notable statistics on first admissions for a drug disorder in 2013 include: 
 The majority were to psychiatric units in general hospitals (250, 69%), followed by 
admissions to psychiatric hospitals (67, 18%) and to private hospitals (48, 13%).   
 10% were involuntary admissions. 
 The rate was higher for men (11.7 per 100,000) than for women (4.3 per 100,000). 
The majority of cases hospitalised for a drug disorder stayed just under one week (51%), while most 
were discharged within three months. It should be borne in mind that admissions and discharges 
represent episodes or events and not persons. 
1.3 Drug related infectious diseases 
1.3.1 Main drug-related infectious diseases among drug users – HIV, HBV, HCV 
 
HIV surveillance, 2014 
Voluntary linked testing for antibodies to HIV has been available in Ireland since 1982 
Figure 1.3.1.1 presents the number of new cases of HIV among people who inject drugs (PWID) 
reported in Ireland, by year of diagnosis; data from 1982 to 1985 are excluded as these four years 
were combined in the source records. According to the most recent report of the Health Protection 
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Surveillance Centre (HPSC), at the end of 2014, 377 people were newly diagnosed with HIV in 
Ireland (crude notification rate of 8.2 per 100,000 population). This marks an increase of 11% since 
2013 and is due to increases in HIV cases among men who have sex with men and PWID.  Prior to 
this, the annual rate of HIV had been stable from 2010 to 2013, ranging from 7.0 to 7.5 per 100,000 
population. 
 
In 2014, 7% (27) of newly-diagnosed HIV cases were PWID. This is the highest number of HIV 
cases among PWID since 2009.  Of these 27 cases, 14 were women and 13 were men.  The 
number of newly diagnosed women has increased from 3 in 2012 to 14 in 2014.    The median age 
was 32 years (range 24 to 49 years). Twenty-three cases were born in Ireland and two in Eastern 
Europe. Country of birth was not unknown for two. Twenty-four (89%) were resident in Dublin. 
Where information is available (11 cases) the median duration of injecting drug use was 8 years. 
Forty-one per cent of newly diagnosed cases of HIV among PWID in 2014 were recent infections, 
having had previous negative HIV tests in either 2013 or 2014; the proportion late diagnoses in 
2014 (44%) was lower than in previous years (53% in 2013 and 56% in 2012). The increased 
incidence of recent HIV infection among PWID is being investigated and a detailed review of the 
mode of transmission conducted.   
Among the PWID newly diagnosed with HIV infection, 89% (24) were co‐infected with hepatitis C 
(Health Protection Surveillance Centre 2015). 
 
Figure 1.3.1.1 Number and rolling average number of new cases of HIV among PWID, by year of diagnosis, 
reported in Ireland, 1986–2014 
Source: Unpublished data reported to Department of Health by National Disease Surveillance Centre and HPSC, 2015 
 
Hepatitis B (HBV) notifications, 2014 
There were 446 notifications of HBV in 2014 compared to 431 in 2013, a 3.5% increase (Table 
1.3.1.1). This increase is likely to be associated with the level of immigration into Ireland. Of the 
cases notified, 60% (270) were male, 38% (169) were female and in a further seven cases the 
gender was unknown. The majority, 70% (313), were aged between 25 and 44 years.  The number 
of acute cases remained low at 30, showing a small decrease since 2012 when there were 37 acute 
cases.  Among acute cases of HBV in 2014, none were injecting drug users. 
 
Table 1.3.1.1   Acute and chronic HBV cases reported to the HPSC, by risk factor status, 2013–14 
 2013 2014 
Hepatitis B status Acute Chronic Unknown Acute Chronic Unknown 
 
N (%) N (%) N (%) N (%) N (%) N (%) 
Total number of cases 31 386 14 30 399 17 
% of cases by status (7.2) (89.6) (3.2) (6.7) (89.4) (3.8) 
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Cases with reported risk factor data 30 230 6 29 250 4 
% of cases with risk factor data (97) (59.6) (42.9) (97) (62.6) (23.5) 
of which          
Injecting drug users 1 (3.3%) 6 (2.6%) 0 (0%) 0 (0%) 4 (1.6%) 0 (0%) 
Cases without reported risk factor data 1 156 8 1 149 13 
% of cases without risk factor data (3) (40.4) (57.1) (3) (37.3) (76.4) 
Total 431 446 
Source: Unpublished data reported to Department of Health by National Disease Surveillance Centre and HPSC, 2015 
 
Hepatitis C (HCV) notifications, 2014 
There were 710 HCV notifications in 2014 (Table 1.3.1.2), a decrease of 16% on 2013 when there 
were 847 notifications. The notification rate for 2014 was 15.5 per 100,000 population.  There has 
been a downward trend in hepatitis C notifications since peak numbers (1,541) were recorded in 
2007.  The median age at notification has increased steadily since notification began in 2004, from 
32 to 39 years among males and from 29 to 36 years among females.  Decreasing HCV 
notifications and increasing median age are indicative of a reduced incidence of HCV in the 
population.  Demographic data in 2014 remained similar to previous years, with 70% (503) of cases 
being male and 85% (601) aged between 25 and 54 years. 
 
Table 1.3.1.2 HCV cases and notification rates per 100,000 population, 2004–2014 
Year n Notification rate 
2004 1119 26.4 
2005 1403 33.1 
2006 1210 28.6 
2007 1541 36.5 
2008 1511 35.8 
2009 1240 29.3 
2010 1236 29.2 
2011 1257 29.6 
2012 1036 24.4 
2013 847 18.5 
2014 710 15.5 
Source: HPSC unpublished data 
Risk factor data were available for 58% (409) of the 2014 cases (Table 1.3.1.3); for 68% (277) of 
these cases, injecting was the predominant risk factor, and of these cases 211 (76%) were men and 
the mean age was 37 years.  Among the 277 cases where injecting was the predominant risk factor, 
76% (211) were men, the mean age was 37 years, and 72% (199) lived in Dublin  or the adjoining 
counties of Kildare and Wicklow (Table 1.3.1.4) 
Table 1.3.1.3 HCV cases reported to the HPSC, by risk factor status, 2010–2014 
Risk factor status 2010 2011 2012 2013 
2014 
  n (%) n (%) n (%) n (%) 
n (%) 
Total number of cases 1236 1257 1036 847 710 
Cases with reported risk 
factor data 
728 (58.8%) 753 (59.9%) 651 (62.8%) 540 (63.8%) 409 (57.6%) 
Of which: 
    
 
Injecting drug users 550 (75.5%) 616 (81.8%) 484 (74.3%) 372 (68.9%) 277 (67.7%) 
Recipient blood/blood 
products 
19 (2.6%) 19 (2.5%) 26 (4%) 16 (3%) 16 (3.9%) 
Other risk factors 143 (19.6%) 106 (14.1%) 127 (19.5%) 135 (25%) 101 (24.6%) 
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Source: HPSC unpublished data 
Table 1.3.1.4 Hepatitis C cases who reported injecting drug use as a risk factor, by age, gender and place of 
residence, 2010–2014 
  2010 2011 2012 2013 2014 
  n (%) n (%) n (%) n (%) n (%) 
Total number of known injector 
cases 
550 616 484 372 277 
Gender 
    
 
Male 409 (74%) 419 (68%) 348 (72%) 272 (73%) 211 (76.1%) 
Female 140 (25.5%) 196 (31.8%) 136 (28%) 99 (26.6%) 66 (23.8%) 
Gender not known 1 1 0 1 0 
Age 
    
 
Mean age 35.8 35.4 36.9 37.6 37 
Median age 34 34 36 37 36 
Under 25 years 32 (5.8%) 45 (7.3%) 23 (4.8%) 10 (2.7%) 19 (6.8%) 
25–34 years 247 (44.9%) 269 (43.7%) 178 (36.8%) 137 (36.8%) 105 (37.9%) 
Over 34 years 271 (49.3%) 300 (48.7%) 282 (58.2%) 225 (60.5%) 153 (55.2%) 
Age not known 0 (0%) 2 (0.3%) 1 (0.2%) 0 (0%) 0 (0%) 
Place of residence 
    
 
Dublin, Kildare or Wicklow 466 (84.7%) 538 (87.3%) 399 (82.4%) 297 (79.8%) 199 (71.8%) 
Elsewhere in Ireland 84 (15.3%) 78 (12.7%) 85 (17.6%) 75 (20.2%) 78 (28.1%) 
Source: HPSC unpublished data 
1.3.2 Additional information on drug-related infectious diseases 
 
Pregnant women with blood-borne infections, 2013  
The DOVE Clinic in the Rotunda Maternity Hospital, Dublin, was established to meet the specific 
needs of pregnant women who have or are at risk of blood-borne or sexually-transmitted bacterial or 
viral infections.  Figures from the clinic for 2013 were published in the hospital’s annual report (The 
Rotunda Hospital 2014).  
In 2013, a total of 206 women were booked into the DOVE clinic for ante-natal care. Of these: 
- 28% (59) were positive for HBV surface antigen (down from 70 in 2012), 
- 28% (59) were positive for HCV antibody (down from 61 in 2012), 
- 12% (24) were positive for HIV (down from 36 in 2012), 
- 10% (20) were positive for Treponemal serology (an increase from 15 in 2012), and 
- 23% (48) were known to be on prescribed methadone programmes (down from 73 in 2012).  
Deliveries to mothers attending the DOVE Clinic are outlined in Table 1.3.2.1.  A total of 78 
deliveries were to mothers attending the drug liaison midwife (DLM), 53 were HBV positive, 58 were 
HCV positive, 30 HIV positive and 10 tested positive for syphilis.  Sixteen babies were admitted to 
the neonatal unit with neonatal abstinence syndrome.   
Table 1.3.2.1 Deliveries to mothers attending the DOVE Clinic who were positive for HIV, HCV, HBV or syphilis or 
who were attending the DLM, 2013 
Mother’s status 
HIV(+ve) HCV(+ve) HBV(+ve) 
Syphilis 
(+ve) 
DLM 
Total Mothers Delivered 30 58 53 10 78 
Total Mothers Delivered <500g (incl 
miscarriage) 
0 7 1 1 5 
Total Mothers Delivered>500g 30 51 52 9 73 
No known risk factor 
identified 
16 (2.2%) 12 (1.1%) 12 (1.8%) 17 (3%) 15 (3.6%) 
Cases without reported risk 
factor data 
511 (41.3%) 504 (40.1%) 385 (37.1%) 307 (36.2%) 301 (42.3%) 
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Live infants 31 53 (inc 3 
NND) 
52 9 74 (inc 1 
set twins) 
Miscarriage 0 5 1 1 5 
Stillbirth 0 0 0 0 0 
Infants <37 weeks gestation 4 12 4 1 16 
Caesarean Section 16 15 17 3 20 
NICU admission for NAS     16 
Maternal median age 34 32 28 34.5  
Newly diagnosed at ANS 6 6 11 2  
Source: (The Rotunda Hospital 2014) 
NICU = Neonatal intensive care unit 
NAS = Neonatal abstinence syndrome 
ANS = Ante-natal screening 
DLM = Drug liaison midwife 
NND = Neonatal death 
 
In 2014 the Coombe Women and Infants University Hospital published its annual report for 2013 
and reported that 309 women attended the Addiction and Communicable/ Infectious Diseases 
service for ante-natal care and post-natal follow-up (Coombe Women and Infants University 
Hospital 2015). Of those attending ante-natal care: 
 42 were positive for HBV, of whom 6 were newly diagnosed; 
 45 were positive for HCV, of whom 11 were newly diagnosed; 
 26 were positive for HIV, of whom 1 was newly diagnosed; and 
 2 were co-infected with HCV, 2 with HBV and 4 with syphilis. 
In terms of addiction, 82 women linked with the DLM, and of these, 68 delivered 69 live babies (one 
set of twins). Of the 69 babies, 48% (33) were admitted to special care and 19 of these required 
pharmacological treatment for NAS.  The report stated that heroin continued to be the primary 
substance used but that cocaine and benzodiazepine use was also evident. 
1.4 Other drug-related health harms 
1.4.1 Other drug-related health harms 
 
National Registry of Deliberate Self Harm Annual Report, 2013  
The 12th annual report from the National Registry of Deliberate Self Harm was published in 
September 2014 (Griffin E, et al. 2014). The report, produced by the National Suicide Research 
Foundation (NSRF), contains information relating to every recorded presentation of deliberate self-
harm to acute hospital emergency departments in 2013, giving complete national coverage of cases 
treated. All individuals who were alive on admission to hospital following deliberate self-harm were 
included, along with the methods of deliberate self-harm that were used.  Accidental overdoses of 
medication, street drugs or alcohol were excluded. 
 
There were 11,061 recorded presentations of deliberate self-harm, involving 8,772 individuals, in 
2013. This implies that one in five (2,289, 21%) of the presentations were repeat episodes. The rate 
of presentations decreased from 211/100,000 in 2012 to 199/ 100,000 in 2013, a 6% decrease.  
However, the rate in 2013 was still 6% higher than the pre-recession rate of 188/100,000 in 2007 
(Figure 1.4.1.1). 
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Figure 1.4.1.1 Person-based rate of deliberate self-harm, by gender, 2002–2013* 
Source: (Griffin E, et al. 2014) 
*‘All’ in the legend refers to the rate for both men and women per 100,000 population. 
 
Forty-six per cent of self-harm presentations in 2013 were men.  Just over half (53%) were aged 
under 30 years. Five hundred and sixteen (5%) self-harm presentations were living in hostels for the 
homeless or had no fixed abode.   Presentations peaked in the hours around midnight and were 
highest on Sundays and Mondays; 31% of episodes occurred on these two days. There was 
evidence of alcohol consumption in 4,037 (36.5%) presentations and this was more common among 
men (40%) than women (34%).  
Drug overdose was the most common form of deliberate self-harm reported in 2013, occurring in 
7,457 (67%) of all such episodes. Overdose rates were higher among women (72%) than among 
men (62%). In 72% of cases the total number of tablets taken was known; an average of 30 tablets 
was taken in these episodes. The average among men was 33 tablets and among women 28 
tablets.   
Thirty-nine per cent of all drug overdoses involved a minor tranquilliser (most commonly 
benzodiazepines), 29% involved paracetamol-containing medicines, 21% involved antidepressants 
or mood stabilisers (most commonly Selective Serotonin Reuptake Inhibitors [SSRIs]), 10% involved 
a major tranquilliser and 27% involved other prescribed drugs. 
The number of presentations involving street drugs in intentional overdose acts (420) was similar to 
the number recorded in 2007 (434).  This reflected a fall of 3% from 2012, a fall of 10% from 2011 to 
2012, and a fall of 27% from 2010 to 2011.  
The next steps, or referral outcomes, for the deliberate overdose cases were: 49% discharged 
home; 29% admitted to an acute general hospital; 7% admitted to psychiatric in-patient care; a small 
proportion (1%) refused admission to hospital; and 14% discharged themselves before receiving 
referral advice.  
The report provided information on what was being or could be done to reduce the number of self-
harm cases.  The total number of presentations involving drug overdose fell by 10% from 2012.  
This was most notable among overdoses involving minor tranquillisers, which fell by 13%.  The 
report related this to proactive monitoring of prescribing patterns in primary care services since 
2012.  The authors recommended that a review the implementation of the paracetamol legislation 
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should also be undertaken in light of the continuing high level of overdose involving paracetamol-
containing medicines.  
The authors reported that alcohol continued to be one of the factors associated with the higher rate 
of self-harm presentations on Sundays, Mondays and public holidays, around the hours of midnight. 
These findings underlined the need for on-going efforts to: 
 enhance health service capacity at specific times and increase awareness of the negative 
effects of alcohol misuse and abuse such as increased depressive feelings and reduced 
self-control; 
 intensify national strategies to increase awareness of the risks involved in the use and 
misuse of alcohol, starting at pre-adolescent age, and intensify national strategies to reduce 
access to alcohol and drugs;  
 educate self-harm patients and their families about the importance of reduced use of and 
access to alcohol; and  
 arrange active consultation and collaboration between the mental health services and 
addiction treatment services in the best interest of patients who present with dual diagnosis 
(psychiatric disorder and alcohol/drug abuse).  
The authors reported that there was variation in the next care recommended to deliberate self-harm 
patients, and in the proportion of patients who left hospital before a recommendation, which ranged 
from 10% in the Dublin/Midlands Hospital Group to 19% in the Dublin North East and North Eastern 
Hospitals Groups.   The National Office of Suicide Prevention has funded pilot projects to implement 
and evaluate suicide and self-harm awareness training for all emergency department staff, and to 
improve assessment procedures for self-harm patients in Cork and Kerry, which is a collaborative 
initiative between Cork University Hospital and the National Suicide Research Foundation. 
The report highlighted the on-going work by the NSRF to link data of deliberate self-harm with 
suicide mortality data.  This linking has shown that individuals who self-harm are over 42 times more 
likely to die by suicide than the general population.  Further linkage is recommended in order to 
enhance insight into predictors of suicide risk. 
1.5 Harm reduction interventions 
1.5.1 Drug policy and main harm reduction objectives 
The current National Drugs Strategy aims to reduce harm arising from substance misuse and to 
reduce the prevalence of blood-borne viruses (BBVs) among people who inject drugs (PWID) 
through the expansion of needle exchange provision to include community pharmacy-based 
programmes. For further details on the National Drugs Strategy, see Section 1.1 of the Policy 
chapter. 
1.5.2 Organisation of Harm reduction services 
There are three models of needle exchange programmes in use in Ireland: 
1. static – 24 sites mainly in Dublin City, 
2. outreach – 14 sites mainly in counties Dublin, Kildare, Laois, Offaly, Waterford and Wicklow, 
and 
3. pharmacy – 63 sites in regions outside Dublin, Kildare and Wicklow, of which 33 had needle 
exchange transactions. 
In a recent study conducted by the HSE, all needle exchange services reported that they provide at 
least five or more of the ten interventions listed below: 
1. Specific harm reduction advice 
2. Overdose awareness 
3. Basic harm reduction messages repeated at each attendance 
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4. Service user referrals to A&E or a GP 
5. Service user referrals to other health, outreach and social care services 
6. Wound care advice 
7. Injection site inspection 
8. Service user referrals for BBV testing and hepatitis B vaccination 
9. Service user assistance with the referral process, e.g. making phone calls 
10. Other health advice 
For further details on the needle exchange programme, see section 1.5.3 below 
1.5.3 Harm reduction services 
 
Needle exchange provision in Ireland, 2012 
The Health Service Executive (HSE) recently published a review of needle exchange provision in 
Ireland (Bingham, et al. 2015).  
 
The review was designed to assess the effectiveness of HSE-funded needle exchange services 
using evidence from 2012.  In particular, the study examined: 
 needle exchange activity nationally in 2012, 
 referral rates to health and social care, 
 data collection procedures and clinical governance, and  
 quality assurance and clinical governance. 
Data were collected between February and June 2013 using a questionnaire consisting of closed 
and open-ended questions.  The data collection template was reviewed to ensure it met the data 
recording requirements of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA).  All six non-statutory needle exchange services and all HSE regional offices returned 
questionnaires.  However, of the 63 pharmacies where needle exchange services were available, 
only 33 had reported transactions in 2012 and of these only 16 returned questionnaires. 
Access 
Pharmacy needle exchange programmes provided a far greater level of accessibility, with 
pharmacies typically open six days per week and providing on average 48 hours of service weekly. 
On the other hand, 15 of the 24 static services opened for less than eight hours and a further seven 
opened for between 25 and 43 hours per week.  Half (7) of all outreach services opened for less 
than 25 hours per week, with a further five open for between 25 and 43 hours and two open 
whenever needed. 
 
Activity 
The review indicated that 13,763 individuals used the needle exchange during 2012, of whom 7,359 
(80%) were men and 1,862 (20%) were women.  However, the authors urged caution as there is no 
unique health identifier in Ireland and as a result service users can be counted more than once.   
A total of 65,099 transactions in needle exchange services during 2012 were reported in the review, 
of which the majority (84%) were in static or outreach services and took place in Dublin North East 
or Dublin Mid Leinster (see Figure 1.5.3.1).  The variation in use of each exchange type was 
proportionate to the services available in the particular area. 
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Figure 1.5.3.1 Number of transactions at needle exchange services by region and model of service, 2012 
Source: (Bingham, et al. 2015) 
 
Paraphernalia distributed 
Detailed information on the quantity of injecting equipment distributed at all sites was made 
available to the reviewers with the exception of two static sites where only partial information was 
available.  Individual items were distributed at the static and outreach services, whereas packs of 
equipment were distributed at the pharmacy-based exchanges.   
Static and outreach services: 
In total, 156,575 syringes and 135,696 needles were distributed.  Almost half of all syringes (49%) 
were fixed needle and 1ml syringes.  In addition, the following items were distributed in 2012: 
Vials of 10ml water for injection            75819 
Vials of 5ml water for injection   8377 
Vials of 2ml water for injection   1572 
Spoons/filters                          25450 
Citric acid                          20125 
Sterile swabs                          20603 
Foil (for smoking heroin)                        12031 
Tourniquets                              476 
 
The review pointed to a discrepancy between the number of needles and quantity of other injecting 
equipment distributed. In particular, the fact that 67,928 more needles than vials of water were 
made available was highlighted.  This, the authors stated, might signal that some equipment was 
being used more than once, contrary to best practice. 
Pharmacy-based needle exchanges: 
In 2012, a total of 11,790 packs, each containing the equipment for 10 sterile injections, were 
distributed at pharmacy-based needle exchanges.  Each pack contained 10 filter syringes (including 
needles), 10 stericups, 10 swabs, 10 citric acid packs, 10 vials with 5ml water for injection and one 
information leaflet (harm reduction and safer injecting advice). 
 
Returns policy 
All services reported that they encouraged the return of used equipment but that this was not a 
condition for accessing new equipment.  All pharmacy-based needle exchanges kept a record of 
equipment returned.  However, the level of record keeping varied across the static and outreach 
services. 
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Referrals and other services 
The review stated that all services reported providing information on BBVs but that recording of the 
numbers referred for testing or for hepatitis B vaccination was inconsistent within the static and 
outreach services. Referrals from the pharmacy-based services were recorded and reported 
systematically. 
 
The number of referrals reported to the review team is outlined in Figure 1.5.3.2, but this is an 
under-estimation of the level of referrals from the static and outreach services. 
 
Figure 1.5.3.2 Number of referrals recorded by model of needle exchange, 2012 
Source: (Bingham, et al. 2015) 
 
All services reported providing face-to-face advice on overdose and harm reduction as well as 
referrals to other treatment and counselling services.  Other services included referral to general 
practitioners, A&E, outreach and social care services as well as wound care and injection site 
inspection.   
Quality assurance 
The review detailed the quality assurance mechanisms in place in the various needle exchange 
services.  Under the Pharmacy Act 2007, the Pharmaceutical Society of Ireland has powers of 
inspection, investigation and enforcement.  All static and outreach needle exchange services work 
within the National Drug Rehabilitation Implementation Committee (NDRIC) framework, which is 
designed to ensure service providers offer individuals affected by drug misuse a range of integrated 
options tailored to meet their needs and create for them an individual rehabilitation pathway.  These 
services were reported as using a range of clinical governance approaches. 
 
Recommendations 
The review recommended that a standardised electronic reporting mechanism for regular monitoring 
and reporting of all needle exchange transactions be considered.  It pointed to the need for a unique 
identifier for each service user to remove the risk of individuals being reported more than once in a 
reporting year.  The need for specific data on injecting of image and performance enhancing drugs 
was highlighted. An examination of the potential barriers to BBV testing and vaccination was 
recommended in order to improve uptake. The review also included a number of recommendations 
with regard to the standards needed to enhance quality assurance and clinical governance. 
Finally, the review recommended the provision of injecting equipment (e.g. stericups, filters and foil) 
in addition to needles and syringes and pointed to the possibility of central purchasing of stock for all 
non-pharmacy needle exchange programme as a means of promoting value for money. 
Pharmacy-based needle exchange in Ireland, 2013 
In October 2011 the HSE rolled out the national pharmacy needle exchange programme, which is a 
partnership initiative between the Elton John Aids Foundation, the Irish Pharmacy Union and the 
Health Service Executive (HSE). The programme targets counties outside Dublin. Once pharmacies 
have signed a service level agreement with the HSE, their contact details are passed on to the 
relevant HSE services so that they can promote access to sterile injecting equipment at the 
participating pharmacies and accept referrals for investigation and treatment.  
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There were 42 pharmacies providing needle exchange at the end of 2011 and this had increased to 
99 by the end of 2013. There were pharmacies providing needle exchange in each regional drugs 
task force area (Table 1.5.3.1), apart from those covering counties Dublin, Kildare and Wicklow, 
which were served by a mix of static and outreach needle-exchange programmes. These data were 
collected from participating pharmacies by the HSE.  
Table 1.5.3.1 Number of pharmacies providing needle exchange by regional drugs task force area, 2011–2013  
Regional drugs task force area 2011 2012 2013 
Midland (Longford, Laois, Offaly, Westmeath) 5 13 15 
North Eastern (Meath, Louth, Cavan, Monaghan) 3 9 16 
North West (Sligo Leitrim, West Cavan, Donegal) 3 4 7 
Southern (Cork and Kerry) 8 10 16 
South East (Carlow, Kilkenny, Waterford, Wexford. South Tipperary) 13 21 22 
Western (Galway, Mayo, Roscommon) 5 2 10 
Mid West (Clare, Limerick, North Tipperary) 5 8 13 
Total 42 67 99 
Source: HSE unpublished data, 2015 
An average of 933 individuals attended pharmacy-based needle exchanges each month in 2013 
(compared to a monthly average of 360 in 2012). The number of individual drug users availing of 
sterile injecting equipment increased from 583 in January 2013 to 1,073 in December 2013 (Figure 
1.5.3.2).   The majority (78%) of individual attenders were male, and had an average age of 32 
years; the average age of female attendees was 30 years.  
 
Figure 1.5.3.2   Number of transactions at pharmacy-based needle exchanges, packs distributed, and used packs 
returned, 2013 
Source: HSE unpublished data, 2015 
 
In 2013 the pharmacy-based needle exchanges provided a link between harm reduction services 
and drug treatment services through referring individuals for BBV testing (402), hepatitis B 
vaccination (262) and to tier three and tier four services (436).  
Merchants Quay Ireland Review 2013 
Merchants Quay Ireland (MQI) is a national voluntary agency providing services for homeless 
people and for drug users. Its needle exchange health promotion unit provides drug users with 
information about risks associated with drug use and the means to minimise such risks.  It also 
provides drug users with a pathway into treatment and the possibility of living life without drugs.  In 
September 2014 MQI published its annual review for 2013 (Merchants Quay Ireland 2014). 
In 2013, there were 25,190 visits to MQI’s Drug Services and 22,898 needle exchanges, which was 
a 10% increase over 2012.  In total, 3,260 individuals used the service, and of these, 614 were new 
clients. A total of 1,748 safer injecting workshops were undertaken with injecting drug users. 
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MQI, in association with the Midland Regional Drugs Task Force and the HSE, administer the 
Midlands Family Support and Community Harm Reduction Service, providing outreach and working 
with families of those actively using drugs in that task force region. The harm reduction service 
worked with 263 clients during 2013, providing 2,975 harm reduction interventions.  An average of 
257 needle exchanges were provided each month during the year. 
 
2. Trends  
2.1 Short term trends in drug-related harms and harm reduction services 
 
a) Trends in drug-induced deaths among adults 
The number of drug-induced deaths has fluctuated over the past five years (2009 to 2013), from 216 
deaths in 2009 to a peak of 232 deaths in 2011; the number then decreased to 189 in 2012 but 
increased again in 2013 to 219. Reasons for the fluctuation are not known. The majority of those 
who died over the period were male, with a gradual increase in mean age from 34.5 years in 2009 
to 36.5 years in 2013 (see also Sections 1.1.1 – 1.1.4 above).   
Opiates continued to be associated with most poisoning deaths over the period.  Of note, the 
number of cases where heroin was implicated increased in 2013 for the first time since 2009, to 86 
deaths. The reason for this increase is not known. 
b) Trends in prevalence and notifications of infectious diseases 
i) HIV – as outlined in Figure 3.2.1 below, there has been an increase in notifications of 
recently acquired HIV among PWID in Dublin, since June 2014.  Clinicians from the 
drug services were concerned that the increase could possibly be linked to injection 
of a synthetic cathinone PVP, with the street name ‘Snow Blow’.  However, 
epidemiological investigations are still under way and it is too early to draw any 
definite conclusions. 
ii) Hepatitis C (HCV) –  as outlined in Section 1.3.1 above, there has been a downward 
trend in HCV notifications since peak numbers (1,541)  were recorded in 2007.  The 
median age at notification has increased steadily since notification began in 2004, 
from 32 to 39 years in males and from 29 to 36 years in females.  Decreasing HCV 
notifications and increasing median age are indicative of a reduced incidence of HCV 
in the population.   
c) Drug-related acute emergencies 
Trends over time indicate a decrease in overdose cases admitted to Irish hospitals, falling from 
5,012 cases in 2005 to 4,233 cases in 2013.  Rate of first-time admission to psychiatric units with a 
diagnosis of drug disorder for 2013 remains similar to that in 2012 at 8 per 100,000 population. 
d) Number of syringes distributed to injecting drug users 
Since the pharmacy-based needle exchange programme was established in October 2011, the 
number of pharmacies providing needle exchange has increased from 42 at the end of 2011 to 99 
by the end of 2013.  The number of people attending these services also increased from on average 
306 per month in 2012 to 933 per month in 2013.  The expansion in these services forms part of 
Action 34 in the current National Drugs Strategy and the increase in numbers reflects the expansion 
in service availability.  Full details of the pharmacy-based needle exchange programme are 
provided in section 1.5.3 above. 
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3. New developments 
3.1 New developments in drug-related deaths 
 
Naloxone demonstration study 
A naloxone demonstration project is currently under way in the country (see 
http://www.drugs.ie/resources/naloxone/ or (Lyons 2014)).  The aim of the project is to assess and 
evaluate the suitability and impact of using naloxone in Ireland in order to make naloxone more 
widely available for problem opiate users. Up to 600 problem opiate users will receive a pre-filled 
syringe of naloxone on prescription along with training on how to administer it and also how to 
recognise the signs of overdose. 
The HSE is commissioning an independent external evaluation of both the processes and outcomes 
of the project. It should be completed by the end of 2015.1  
The aim of the process evaluation is to determine the nature and quality of the programme 
implemented by examining: 
1.       the implementation of the main elements of the programme, 
2.       the nature and quality of the training sessions, and  
3.       participants’ views of the programme as a whole. 
 
The aim of the outcome evaluation is to explore: 
1.       learning and other outcomes from the training sessions,  
2.       practical application of naloxone in overdose events,  
3.       practical application of other harm-reduction actions in overdose events, and 
4.       the effect of naloxone in reducing the number of fatal overdoses. 
 
3.2 New developments in drug-related infectious diseases 
 
Increase in diagnoses of recently acquired HIV in people who inject drugs in Dublin  
In July 2015 the Health Protection Surveillance Centre (HPSC) reported that an increase in 
notifications of recently acquired HIV among people who inject drugs (PWID) in Dublin, had been 
occurring since June 2014 (Health Protection Surveillance Centre 2015). The report defined recently 
acquired HIV infections as those in which the person who tests positive is p24 antigen positive, or 
has had an HIV negative test within the previous 12 months or suffers an acute HIV sero-conversion 
illness. Clinicians from the drug services were concerned that the increase could possibly be linked 
to injection of a synthetic cathinone PVP, with the street name ‘Snow Blow’.  In response, an 
epidemiological investigation was instigated. 
 
The report stated that 15 cases of recently acquired HIV infection (confirmed cases) and one case 
with an epidemiological link to a recently acquired HIV infection (probable case) diagnosed among 
PWID had been reported between June 2014 and June 2015 (Figure 3.2.1).  Of these, 11 were 
male and five were female, and the mean age was 35 years (range 24 to 51 years). Of the 15 
confirmed cases, seven were p24 antigen positive, indicating very recent infection. At the time of 
reporting, a further 16 possible cases were under investigation and new cases continued to be 
detected.  
                                                          
1
 See http://www.drugs.ie/news/article/extended_deadline_to_initial_call_evaluation_of_the_hse_naloxone_demonstrat 
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Figure 3.2.1 Number of confirmed and probable HIV diagnoses among PWID in Dublin by month of first diagnosis, 
June 2014–June 2015 (N=16) 
In response to the increased incidence of HIV, the following immediate control measures are being 
implemented: 
 provision of antiretroviral therapy to PWID diagnosed with HIV, where possible, and contact 
tracing to detect any additional cases among sexual or drug sharing partners; 
 review of clients attending drug services, to identify those most at risk, and offering urgent 
HIV testing; 
 pilot point of care testing (POCT) of PWID clients attending the Safety Net homelessness 
services; 
 enhanced surveillance to identify new HIV cases as early as possible, including mode of 
transmission; 
 awareness raising among clients, clinicians, networks of PWID and other stakeholders; 
 provision of greater access to needle exchange and other preventive activities within the 
drugs and homelessness hostel services and prisons.  The need for additional measures, 
including the provision of extended opening hours for needle exchange, is being evaluated;  
 development and distribution of communications material, aimed at raising awareness of the 
risk of HIV among PWID, posed by unsafe injections and unsafe sex. This is available on the 
HPSC website; 
• active case finding including Recent Infection Testing of possible cases; and 
• phylogenetic analysis of cases. 
 
3.3 New developments in harm reduction interventions 
 
Low-threshold residential stabilisation service (LTRSS) demonstration projectIn June 2014 
the Ana Liffey Drugs Project (ALDP) published a position paper proposing the provision, on a three-
year demonstration basis, of a low-threshold residential stabilisation service (LTRSS). The paper 
outlines the concept of LTRSS and how this differs from current services as well as describing how 
the service would operate and the steps required to begin implementation (Ana Liffey Drug Project 
2015). The ALDP is currently seeking funding and a premises to operate the service on a 
demonstration basis for three years beginning in 2017. 
The overall aim of an LTRSS is to provide a ‘genuine person-centred service, catering for those with 
greatest need’.  The paper describes LTRSS as follows: 
 low threshold – barriers to entry are kept as low as possible;  
 residential – medically-led inpatient programme, with psycho-social support and follow-up care;  
0
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 stabilisation – stabilising the individual’s drug use, as well as providing detoxification (if 
appropriate) and referral to community or residential services;  
 access to the service based on individual need, as measured by a comprehensive assessment 
tool; and  
 time-bound (no more than a 28-day stay), but flexible to meet the client’s needs. 
 
The proposed new service is described as differing from services currently available in Ireland in 
that it is open access, based on a holistic assessment of need and not determined by the 
individual’s drug use.  There would be no cost to the client.  Outcomes would not be solely clinically 
based but would also focus on enhanced stability.   
The paper argues that services for polydrug users require particular attention.  Polydrug use is a 
significant factor in drug-related deaths and as Ireland has one of the highest rates of drug-related 
deaths in Europe, there is a very strong rationale for the development of residential services which 
are not restricted to single drug use and which are responsive to the chaotic lifestyles of polydrug 
users.  The paper states that polydrug users’ access to the majority of existing residential 
stabilisation and detoxification services is restricted, and that an LTRSS would provide a more 
flexible treatment model adapted to the needs of this particular at-risk group. 
At the same time, the paper recognises that the client’s presenting needs, as opposed to the 
potential clinical outcome, should be the primary determinant of service provision. The paper lists 
patient characteristics that can help determine whether a client is likely to benefit from in-patient 
provision.  These include: 
 dependence on more than one drug, 
 physical complications, 
 co-morbidity, 
 history of complications during previous withdrawals, 
 chaotic polydrug use, 
 pregnancy, 
 failed outpatient withdrawal, and 
 inability to cope with out-patient withdrawal owing to isolation, homelessness or lack of support. 
The proposed LTRSS would target those presenting with these characteristics through a 
comprehensive assessment process. 
The LTRSS would provide a 24-hour, seven-days-a-week programme based on the following 
principles: 
 Access based on the person’s need at the time of presentation: when a bed becomes available, 
the person with the greatest need would be offered a place; there would be no waiting list.  
 Limited length of stay:  maximum stay of approximately 28 days depending on need; the goal 
would be stabilisation with an option for detoxification. 
 Type or level of drug use not a barrier to entry: Polydrug users and those with comorbid mental 
health issues will not be excluded except where the individual’s mental or physical health is a 
barrier to their receiving the stabilisation service. 
4. Notes and queries 
4.1 Evidence of an increase in acute emergencies or deaths related to stimulants   
Drug-induced deaths – small increase in the number of deaths where cocaine was implicated – see 
Section 1.1.2 above. 
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No increase in acute emergencies but a reduction in overdoses involving cocaine from 82 in 2011, 
to 71 in 2012 and 60 in 2013. 
5. Sources and references 
5.1 Sources 
Established in 2005, the National Drug-Related Death Index (NDRDI), which is maintained by the 
HRB, is an epidemiological database which records cases of death by drugs poisoning, and deaths 
among drug users in Ireland, extending back to 1998. The NDRDI also records data on alcohol-
related poisoning deaths, deaths among those who are alcohol dependent, extending back to 2004. 
The Health Protection Surveillance Centre (HPSC) is Ireland’s specialist agency for the 
surveillance of communicable diseases. Part of the Health Service Executive (HSE), and originally 
known as the National Disease Surveillance Centre, the HPSC endeavours to protect and improve 
the health of the Irish population by collating, interpreting and disseminating data to provide the best 
possible information on infectious disease. The HPSC has recorded new cases among injecting 
drug users of HIV since 1982, hepatitis B (HBV) since 2004, and hepatitis C (HCV) since 2006.  
The HIPE (Hospital In-Patient Enquiry) is a computer-based health information system, managed 
by the Economic and Social Research Institute (ESRI) in association with the Department of Health 
and the HSE. It collects demographic, medical and administrative data on all admissions, 
discharges and deaths from acute general hospitals in Ireland. It was started on a pilot basis in 1969 
and then expanded and developed as a national database of coded discharge summaries from the 
1970s onwards. Each HIPE discharge record represents one episode of care; each discharge of a 
patient, whether from the same or a different hospital, or with the same or a different diagnosis, 
gives rise to a separate HIPE record. The scheme, therefore, facilitates analyses of hospital activity 
rather than of the incidence of disease. HIPE does not record information on individuals who attend 
accident and emergency units but are not admitted as inpatients.  
The National Psychiatric In-Patient Reporting System (NPIRS), administered by the Health 
Research Board (HRB), is a national psychiatric database that provides detailed information on all 
admissions to and discharges from 56 inpatient psychiatric services in Ireland. It records data on 
cases receiving inpatient treatment for problem drug and alcohol use. NPIRS does not collect data 
on the prevalence of psychiatric comorbidity in Ireland. The HRB publishes an annual report on the 
data collected in NPIRS, entitled Activities of Irish psychiatric units and hospitals. 
The National Self-Harm Registry Ireland is a national system of population monitoring for the 
occurrence of deliberate self-harm, established at the request of the Department of Health and 
Children by the National Suicide Research Foundation. Since 2006/07 the Registry has achieved 
complete national coverage of hospital-treated deliberate self-harm. The Registry defines deliberate 
self-harm as ‘an act with non-fatal outcome in which an individual deliberately initiates a non-
habitual behaviour, that without intervention from others will cause self-harm, or deliberately ingests 
a substance in excess of the prescribed or generally recognised therapeutic dosage, and which is 
aimed at realising changes that the person desires via the actual or expected physical 
consequences’. All methods of deliberate self-harm are recorded in the Registry, including drug 
overdoses and alcohol overdoses, where it is clear that the self-harm was intentionally inflicted. All 
individuals who are alive on admission to hospital following a deliberate act of self-harm are 
included. Not considered deliberate self-harm are accidental overdoses, e.g. an individual who 
takes additional medication in the case of illness, without any intention to self-harm; alcohol 
overdoses alone, where the intention was not to self-harm; accidental overdoses of street drugs 
(drugs used for recreational purposes), without the intention to self-harm; and individuals who are 
dead on arrival at hospital as a result of suicide.  
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Annual reports for maternity hospitals and for voluntary agencies such as Merchants Quay Ireland. 
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European Monitoring Centre for Drugs and Drug Addiction 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a decentralised EU 
agency based in Lisbon.  The EMCDDA provides the EU and its Member States with information on 
the nature, extent, consequences and responses to illicit drug use. It supplies the evidence base to 
support policy formation on drugs and addiction in both the European Union and Member States.   
There are 30  National Focal Points that act as monitoring centres for the EMCDDA.  These focal 
points gather and analyse country data according to common data-collection standards and tools 
and supply these data to the EMCDDA. The results of this national monitoring process are supplied 
to the Centre for analysis, from which it produces the annual European drug report and other 
outputs. 
 
The Irish Focal Point to the EMCDDA is based in the Health Research Board.  The focal point 
writes and submits a series of textual reports, data on the five epidemiological indicators and supply 
indicators in the form of standard tables and structured questionnaires on response-related issues 
such as prevention and social reintegration.  The focal point is also responsible for implementing 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances. 
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